Geron's spinal injury drug developed cysts in animals, but shares still rise Print E-mail
By Jude Santos and Wire Reports   
Friday, 28 August 2009 04:25

Geron Corporation (NASDAQ:GERN) said animals injected with its experimental cell therapy for subacute spinal cord injury developed microscopic cysts in the injury site, but its shares rose as the company reported none of the animals developed teratomas, a kind of tumor.

Shares for the company Geron Corporation still rose to $7.18 +0.25 (3.61%) despite the news.

"I believe that since the worst case scenario (teratomas) did not occur, investors are relieved," Merriman Curhan Ford analyst Joseph Pantginis said.

As embryonic stem cells are living cells that divide, there is a fear that they can grow uncontrollably and cause tumor if they lose a particular molecular checkpoint, he said. The company said the cysts were non-proliferative, confined to the injury site, and had no adverse effects on the animals.

Geron said on Thursday that another just completed animal study showed a higher frequency of cysts, although their characteristics were similar to the cysts seen in previous studies.

However, a manufactured lot of the drug GRNOPC1 that was assessed using new markers and assays showed no cysts in a recently concluded study in rats, the company said in a statement.

Geron said it submitted these data to the U.S. Food and Drug Administration and is in discussions with the agency to answer its questions and proceed with the clinical trial.

Last week Geron's investigational new drug application was placed on clinical hold by U.S. health regulators to review new nonclinical animal study data submitted by the company.

"The potential timing of a release of the clinical hold is a complete black box and cannot be projected," said Pantginis, who had already removed the spinal cord injury treatment from his valuation model.

"Geron is especially vulnerable because it is at the forefront, by far, of the embryonic stem cell space, and being on the cutting edge means the company must also be the first to hit the hurdles and learn as they go," he said.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter